Class summary at a glance.

Every drug in the Calcineurin Inhibitor Immunosuppressant class tracked across NADAC, Part D Formulary, Part D Spending, FDA Orange Book, and shortage data. Ranked below by CY24 Part D spend. Click any molecule for the full drug profile.

Molecules in class: 5tracked in Part D
CY24 Part D spend: $2.74Bcombined across class
Total Rx claims: 4.7M2.0M unique beneficiaries
Generic mfrs (active): 32across all molecules

Every drug in this class, ranked by Part D spend.

CY2024 dataCMS Part D Spending Dashboard

Cyclosporine

Brand: CEQUA · 3.5M Part D claims (CY24) · 1.4M beneficiaries · First FDA approval: 1983-11-14

15 generic mfrs 2589 plans require PA

Low NADAC$0.310

→

Avg plan cost$5.30

Part D spend $2.51B 17× spread, current vs floor

Class share

92%

of class CY24 spend

View profile →

Tacrolimus

Brand: Envarsus · 1.0M Part D claims (CY24) · 464K beneficiaries · First FDA approval: 1994-04-08

15 generic mfrs 2555 plans require PA

Low NADAC$0.154

→

Avg plan cost$0.687

Part D spend $156.6M 4× spread, current vs floor

Class share

of class CY24 spend

View profile →

Voclosporin

Brand: LUPKYNIS · 3K Part D claims (CY24) · 647 beneficiaries · First FDA approval: 2021-01-22

Brand-only (no generics) 22 plans require PA

Low NADAC—

→

Avg plan cost—

Part D spend $41.3M

Class share

of class CY24 spend

View profile →

Pimecrolimus

120K Part D claims (CY24) · 76K beneficiaries · First FDA approval: 2018-11-26

2 generic mfrs 106 plans require PA

Low NADAC$2.69

→

Avg plan cost$3.22

Part D spend $27.2M 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Cyclosporine Ophthalmic Solution

Brand: VEVYE · — Part D claims (CY24) · First FDA approval: 2023-12-01

Brand-only (no generics) 0 plans require PA

Low NADAC$368.54

→

Avg plan cost$368.54

Part D spend — 1× spread, current vs floor

Class share

of class CY24 spend

View profile →

Class summary at a glance.

Every drug in this class, ranked by Part D spend.

Related questions.